A Medicare beneficiary who has both severe obesity and one of the medical conditions that GLP-1 drugs are approved to treat can be disqualified from the $50 monthly price on those same drugs. That design feature, buried in the fine print of the Medicare GLP-1 Bridge, is now producing denials, and KFF Health News has documented the mechanism in detail.
The rule works like this. The $50 Bridge price applies only when a GLP-1 is prescribed solely for weight loss. Anyone carrying a diagnosis that the Food and Drug Administration has approved these drugs to treat, such as type 2 diabetes or moderate to severe obstructive sleep apnea, is routed back to their own Part D plan instead, where copays commonly run several hundred dollars a month.
